Traditionally, the main goal of BCI has been to replace or restore useful functions to people disabled by neuromuscular disorders. However, recent studies have shown that the technology may have useful applications for mental health disorders as it allows for a direct decoding of emotional experience from neural activity. In the case of Psyber, EEG-based BCI development will be enabled through a tailored software platform and a large patent portfolio, combined with atai's diverse compounds. "At atai, we firmly believe that giving power back to the patient could lead to improved health outcomes," said David Keene, Digital Therapeutics Lead of atai. "This novel technology is designed to do exactly that, combining both medicine and BCI-assisted therapy puts the patient firmly in the driving seat as it tailors to the individual's specific needs."